Precision Regression and Viral Clearance: The Clinical Breakthrough of PVX4 DNA Electroporation in CIN2/3

Model: PVX4

Booth No: M534

Characteristic

PVX4 specifically targets high-grade cervical precancerous lesions, aiming to spare patients from surgical intervention by achieving viral clearance and lesion regression through a combination of DNA therapy and electroporation. The drug candidate has currently advanced to multi-national, multi-center Phase II clinical trials. Through robust clinical collaborations with top medical centers in Taiwan, coupled with deep integration with world-class medical institutions such as Einstein Medical Center in the United States, Papivax not only ensures the global applicability of its clinical data but has also established a high-standard system compliant with international regulations, laying a solid foundation for pushing the drug into the global market.